Let’s work together
At Zikani Therapeutics, we are eager to collaborate with academic institutions and other companies who are interested in the development of Ribosome Targeting Molecules with a focus on treating patients that have currently limited options. We believe that collaborative alliances are the most effective way to develop new medicines. If you would like to discuss working together, we’d be delighted to speak with you.
Learn about our science
Our platform, published in Nature in 2016, allows for the synthesis of novel ribosome-targeting molecules from basic chemical building blocks. This enables us to rationally design the desired activity into our compounds.